Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiploma Regulatory News (DPLM)

Share Price Information for Diploma (DPLM)

Share Price is delayed by 15 minutes
Get Live Data
7,130.00    80.00 (1.13%)
Bid:
7,110.00
Ask:
7,120.00
Spread: 10.00 (0.141%)
Market Cap: £9.56b
DPLM Live PriceLast checked at - London Stock Exchange

Intraday Diploma Share Chart

Interim Management Statement

13 Jan 2010 07:00

RNS Number : 4316F
Diploma PLC
13 January 2010
Β 

ο»Ώ

DIPLOMAΒ PLC

12 CHARTERHOUSE SQUARE,Β LONDON EC1M 6AX

TELEPHONE: +44 (0)20 7549 5700

FACSIMILE: +44 (0)20 7549 5715

FOR IMMEDIATE RELEASE

13 January 2010

DIPLOMA PLC

INTERIM MANAGEMENT STATEMENT

Diploma PLC, the international group of businesses supplying specialised technical products and services, is today issuing its first Interim Management StatementΒ of itsΒ new financial year, ahead of the Company's AGM to be held today at Brewers Hall, Aldermanbury Square, London, EC2V 7HR at 12.00 midday. This Statement relates to the period from 1 October 2009 toΒ dateΒ and includes the first quarter's trading.

Trading

The Group has made a solid start to the new financial year with further evidence that key markets have stabilised. Revenues in the first quarter were 7% ahead of the comparable period last year and operating margins continued to benefit from cost reductions implemented last year. On an underlying basis, adjusting for currency effects and the acquisition of RTD Seals in January 2009, revenues for the first quarter remained unchanged from last year.Β 

The Life Sciences sector reported revenues 16% ahead of the prior comparable period driven by further growth in the Canadian Healthcare businesses and currency benefits. Revenue from the European environmental business remained stable.

The Seals sector reported revenues 11% ahead of the prior comparable period, benefiting from a full quarter contribution from RTD Seals; after adjusting for the acquisition of RTD Seals and currency effects, revenues were 4% below the comparable prior period. In North America and the UK, underlying revenues have stabilised and are showing signs of recovery. However, Continental European revenues were well below strong prior year comparatives, reflecting the later arrival of the economic downturn in these markets last year.

The ControlsΒ sector reported revenues 3% below the comparable prior period, again largely reflecting strongΒ prior yearΒ comparatives from theΒ ContinentalΒ European businesses. The UK businesses achieved revenues broadly in line with the comparable period last year,Β with strong sales to Military Aerospace and Defence offsetting weaker activity in theΒ generalΒ Industrial markets.Β 

Disposal of Anachem LimitedΒ 

The Group completed the disposal of the Manual Liquid Handling business of Anachem on 7 January 2010, as previously announced in the Group's Preliminary Statement on 16 November 2009.Β Cash proceeds ofΒ Β£7.8m were receivedΒ on completion,Β of which Β£0.8m will beΒ held in escrow. Further sale proceeds of up to Β£0.8m may be receivable, depending on the revenues earned in the twelve months ending 31 December 2010.

Acquisition of Minority Interests

Pursuant to the Sale and Purchase Agreement for the acquisition of Somagen Diagnostics Inc, dated 15 July 2004, the Group has now completed the acquisition of the final 8.8% of the outstanding shares in Somagen Diagnostics Inc from the minority shareholders for consideration of Β£2.5m (C$4.3m), following the exercise of put/callΒ 

options, agreed at the time of acquisition. The Group's shareholding in Somagen Diagnostics Inc has now increased from 91.2% to 100%. The Group has also paid dividends to minority shareholders ofΒ caΒ Β£1.0m, of which Β£0.4m was paid during December 2009.

Financial Position

The improvement in underlying trading, together with the continuing focus on carefully managing any expansion in working capital, has resulted in another quarter of strong cash flow. At 31 December 2009, the Group's cash balances had increased toΒ ca.Β Β£25.0m; this is before accounting for the proceeds from the sale of the Anachem business and the purchase of the minority interests in Somagen.

The Group also maintains a committed multi-currency facility of Β£20m which expires in November 2010; this will be reviewed during the next six months.

There have been no other significant changes in the position of the Group in the period since the publication of the Annual Report for the year ended 30 September 2009.

The next update on trading is expected to be issued as part of the Half Year results for the six months ending 31 March 2010, which are expected to be released on 10 May 2010.

Notes:

This Interim Management Statement, which is based upon unaudited management accounts, has been prepared solely to provide additional information to the shareholders of Diploma PLC in order to meet the requirements of theΒ UKΒ Listing Authority's Disclosure and Transparency Rules. It should not be relied on by any other party, for other purposes.

A copy of this Statement, together with further information about Diploma PLC, may be viewed on its website at www.diplomaplc.com

For further enquiries please contact:
Β 
Β 
Β 
Bruce Thompson, Chief Executive Officer
020 7549 5700
Nigel Lingwood, Group Finance Director
020 7549 5705
Simon Bloomfield, Bankside Consultants
020 7367 8861

Β 

NOTE TO EDITORS:

Diploma PLCΒ is an international group of businesses supplying specialised technical products and services to the Life Sciences, Seals and Controls industries.

Diploma achieves stable growth and attractive margins from its focus on supplying specialised technical products to markets which value high levels of customer service, technical support and value adding activities. A high proportion of revenues are generated from essential products and services funded by operating, rather than capital budgets.

The Group employs ca. 825 employees and its principal operating businesses are located in the UK, Germany, US and Canada.

Over the last five years, the Group has grown adjusted earnings per share at an average of ca.Β 16% p.a. through a combination of organic growth and acquisitions. The current market capitalisation is ca. Β£200m.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSEASFAFLAEEFF
Date   Source Headline
14th Feb 202510:34 amRNSHolding(s) in Company
17th Jan 20259:34 amRNSDirector/PDMR Shareholding
15th Jan 20252:56 pmRNSResult of AGM
15th Jan 202510:19 amRNSAppointment of Non-Executive Director
15th Jan 20257:00 amRNS1st Quarter Results
10th Jan 20258:56 amRNSDirector/PDMR Shareholding
23rd Dec 20247:00 amRNSDirector/PDMR Shareholding
9th Dec 20247:00 amRNSAnnual Financial Report & Notice of AGM
5th Dec 20244:25 pmRNSHolding(s) in Company
3rd Dec 20244:39 pmRNSHolding(s) in Company
2nd Dec 20247:00 amRNSTotal Voting Rights
27th Nov 20247:00 amRNSBoard Committee Changes
27th Nov 20247:00 amRNSDirector/PDMR Grant of LTIP Awards
20th Nov 20247:00 amRNSDirector/PDMR Shareholding
20th Nov 20247:00 amRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSPreliminary Results
15th Nov 20247:00 amRNSIssue of Shares & Total Voting Rights
8th Oct 20247:00 amRNSAppointment of Non-Executive Director
13th Sep 20247:00 amRNSAppointment of Senior Independent Director
29th Jul 20242:25 pmRNSDirector Declaration
18th Jul 20247:00 amRNSQ3 Trading Statement
16th Jul 20247:00 amRNSBoard Changes
4th Jun 202411:18 amRNSHolding(s) in Company
13th May 20247:00 amRNSHalf Year Results
2nd May 20247:00 amRNSAcquisition
25th Apr 20243:54 pmRNSHolding(s) in Company
3rd Apr 20247:00 amRNSHolding(s) in Company
27th Mar 20247:00 amRNSAcquisition
5th Mar 20242:07 pmRNSHolding(s) in Company
17th Jan 20243:21 pmRNSResult of AGM
17th Jan 20247:00 amRNSQ1 trading update
20th Dec 20237:00 amRNSAppointment of Non-Executive Director
18th Dec 20237:00 amRNSDirector/PDMR Shareholding
14th Dec 202311:31 amRNSHolding(s) in Company
11th Dec 20237:00 amRNSAnnual Financial Report & Notice of AGM
5th Dec 20233:00 pmRNSDirector/PDMR Shareholding
1st Dec 20237:00 amRNSTotal Voting Rights
28th Nov 20237:00 amRNSDirector/PDMR Grant of LTIP Awards
21st Nov 20237:00 amRNSDirector/PDMR Shareholding
20th Nov 20237:00 amRNSFull Year Results
16th Nov 20237:00 amRNSIssue of Shares & Total Voting Rights
10th Oct 202312:29 pmRNSHolding(s) in Company
21st Aug 202310:10 amRNSHolding(s) in Company
15th Aug 20233:54 pmRNSHolding(s) in Company
18th Jul 20237:00 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSStrategic acquisition in European Fluid Power
13th Jul 20237:00 amRNSQ3 Trading Update
27th Jun 20237:00 amRNSCapital Markets Seminar
13th Jun 20235:09 pmRNSHolding(s) in Company
7th Jun 20233:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.